Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
Autore:
Furuta, T; Ohashi, K; Kamata, T; Takashima, M; Kosuge, K; Kawasaki, T; Hanai, H; Kubota, T; Ishizaki, T; Kaneko, E;
Indirizzi:
Hamamatsu Univ, Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan Hamamatsu Univ Hamamatsu Shizuoka Japan 4313192 , Shizuoka 4313192, Japan HamamatsuJapan, Sch Med, Dept Clin Pharmacol, Hamamatsu, Shizuoka 4313192,Hamamatsu Univ Hamamatsu Shizuoka Japan 4313192 amatsu, Shizuoka 4313192, Hamamatsu Univ, Sch Med, Dept Med 2, Hamamatsu, Shizuoka 4313192, Japan Hamamatsu Univ Hamamatsu Shizuoka Japan 4313192 , Shizuoka 4313192, Japan Hondaapanor Co Ltd, Hamamatsu Hlth Serv Ctr, Hamamatsu, Shizuoka 4338501, J Honda Motor Co Ltd Hamamatsu Shizuoka Japan 4338501 , Shizuoka 4338501, J SRL Inc, Hachioji Lab, Res Testing Dept, Hachioji, Tokyo 1928535, Japan SRL Inc Hachioji Tokyo Japan 1928535 Dept, Hachioji, Tokyo 1928535, Japan Int Med Ctr Japan, Tokyo, Japan Int Med Ctr Japan Tokyo JapanInt Med Ctr Japan, Tokyo, Japan
Titolo Testata:
ANNALS OF INTERNAL MEDICINE
fascicolo: 12, volume: 129, anno: 1998,
pagine: 1027 - 1030
SICI:
0003-4819(199812)129:12<1027:EOGDIO>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
S-MEPHENYTOIN 4'-HYDROXYLATION; DOUBLE-BLIND TRIAL; AMOXICILLIN; JAPANESE; CLARITHROMYCIN; METRONIDAZOLE; POLYMORPHISM; POPULATION; MANAGEMENT; DISEASE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Furuta, T Hamamatsu13192, Sch Med, Dept Med 1, 3600 Handa Cho, Hamamatsu, Shizuoka 43 Hamamatsu Univ 3600 Handa Cho Hamamatsu Shizuoka Japan 4313192 3
Citazione:
T. Furuta et al., "Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer", ANN INT MED, 129(12), 1998, pp. 1027-1030

Abstract

Background: Omeprazole is metabolized by S-mephenytoin 4'-hydroxylase (CYP2C19) in the liver. In persons with a poor-metabolizer genotype for CYP2C19, the therapeutic efficacy of omeprazole may be increased. Objective: To investigate whether CYP2C19 genotype status is associated with cure rates for Helicobacter pylori infection and peptic ulcer achieved by using dual therapy with omeprazole and amoxicillin. Design: Prospective cohort study. Setting: University hospital and health service center in Hamamatsu, Japan. Patients: 62 patients with peptic ulcer and H. pylori infection. Intervention: Omeprazole and amoxicillin,Measurements: CYP2C19 genotype status and cure rates for H. pylori infection and peptic ulcer. Results: Cure rates for H. pylori infection were 28.6% (95% CI, 13.1% to 48.7%), 60% (CI, 38.6% to 83.0%), and 100% (CI, 66.4% to 100%) in the rapid-, intermediate-, and poor-metabolizer groups, respectively. Healing rates for both duodenal and gastric ulcer in the three groups were roughly parallel with cure rates for H. pylori infection. Conclusion: The results of the genotyping test for CYP2C19 seem to predictcure of H. pylori infection and peptic ulcer in patients who receive dual therapy with omeprazole and amoxicillin.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 09:27:31